Beta-Adrenergic Blockers: Receptor Subtypes, Mechanisms, Indications and Safety

Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information. Mechanistic overview Beta blockers antagonize adrenergic β receptors and differ in β1 selectivity, lipid solubility, intrinsic sympathomimetic activity and ancillary α1 antagonism. β1 receptors regulate cardiac rate, force and renin release; β2 receptors affect bronchial/vascular smooth muscle…

Read Full News

Alpha-Adrenergic Blockers: BPH, Pheochromocytoma, Receptors and Safety

Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information. Overview Alpha blockers antagonize α-adrenergic signaling in vascular or urogenital smooth muscle. Their principal current uses are lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH), selected pheochromocytoma preparation and limited cardiovascular settings. These drugs generally…

Read Full News

Sympathomimetics: Adrenergic Receptors, Epinephrine, Vasopressors and Bronchodilators

Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information. Overview Sympathomimetics enhance sympathetic effector responses by directly stimulating adrenergic receptors, indirectly increasing endogenous norepinephrine, or combining both mechanisms. They are indispensable in anaphylaxis, shock, acute bronchospasm and selected hypotensive or cardiac conditions, but their receptor selectivity…

Read Full News

Anticholinergic Drugs: Muscarinic Blockade, Clinical Uses and Anticholinergic Burden

Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care. Overview and terminology Anticholinergic drugs inhibit acetylcholine signaling, but the term should be used precisely. Most medicines called ‘anticholinergics’ in clinical practice are muscarinic receptor antagonists; nicotinic ganglion blockers and neuromuscular blockers are mechanistically distinct groups….

Read Full News

Parasympathomimetics: Cholinergic Agonists, Acetylcholinesterase Inhibitors and Safety

Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care. Overview Parasympathomimetics reproduce selected effects of acetylcholine at muscarinic receptors or increase endogenous acetylcholine by acetylcholinesterase (AChE) inhibition. Because AChE inhibition also increases transmission at nicotinic neuromuscular junctions and autonomic ganglia, indirect cholinomimetics are broader than…

Read Full News

Skeletal Muscle Relaxants: Spasticity Drugs, Neuromuscular Blockade and Reversal

Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care. Overview The phrase ‘skeletal muscle relaxants’ covers fundamentally different drugs: centrally acting agents for painful spasm or spasticity, peripheral agents acting within muscle or motor terminals, and neuromuscular blocking agents (NMBAs) used for anesthesia. Paralysis is…

Read Full News

Local Anesthetics: Sodium Channel Blockade, Regional Techniques and LAST Management

Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care. Overview Local anesthetics (LAs) reversibly block nerve conduction, enabling infiltration, topical anesthesia, peripheral nerve blocks and neuraxial techniques without necessarily altering consciousness. Safe use requires knowledge of agent potency, concentration, total administered dose, injection site, patient…

Read Full News

General Anesthetics: Intravenous and Inhaled Agents, Monitoring and Major Emergencies

Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care. Overview and components General anesthesia produces a controlled state of unconsciousness and unresponsiveness. Its components may include hypnosis, amnesia, analgesia, autonomic stability and immobility, but no single drug reliably provides every component. In particular, neuromuscular blockers…

Read Full News

Enoxaparin Monograph: Anticoagulant Mechanism, Dosing, Renal Adjustment and Safety

Evidence-informed medical pharmacology article updated 10 November 2026. For education; prescribing requires current local labeling and individual patient assessment. Overview and clinical role Enoxaparin is a low-molecular-weight heparin (LMWH) used to prevent and treat venous thromboembolism and in selected acute coronary syndrome regimens. It is an anticoagulant, not a thrombolytic, and does not directly dissolve…

Read Full News

Ezetimibe Monograph: NPC1L1 Inhibition, LDL Reduction and Cardiovascular Use

Evidence-informed medical pharmacology article updated 10 November 2026. For education; prescribing requires current local labeling and individual patient assessment. Overview Ezetimibe is a nonstatin LDL-cholesterol-lowering agent that blocks intestinal cholesterol uptake. It can be used as an adjunct to statins when LDL-C goals are not achieved, and as an alternative or component of treatment when…

Read Full News